Sun Pharmaceutical (SUNPHARMA) — Board Meeting

Sun Pharmaceutical's Board approved Q2 FY2025-26 results on November 5, 2025, reporting consolidated revenues of ₹144,052 million (up 8.6% YoY) and net profit of ₹31,180 million (up 2.6% YoY). EBITDA grew 14.9% to ₹45,271 million with a 31.3% margin. Key corporate actions include NCLT-approved merger of five subsidiaries effective October 7, 2025, Incyte settlement for LEQSELVI™, and Checkpoint Therapeutics acquisition. Exceptional charges included ₹2,876.4 million for SCD-044 discontinuation and US restructuring costs.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUNPHARMA ✨ Ask AI About This

About Sun Pharmaceutical Industries Limited (SUNPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹4,50,643.09 Cr P/E: 41.3 ROE: 15.1% ROCE: 20.3%

View full SUNPHARMA stock details →

📡 Get AI alerts when SUNPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUNPHARMA — Free

💡 Ask AI about this filing

"How does this board meeting affect Sun Pharmaceutical Industries Limited's outlook?" "What did Sun Pharmaceutical Industries Limited announce on 5 November 2025?" "Is this positive or negative for SUNPHARMA?"

Ask AI Free →

📊 More SUNPHARMA filings

See all SUNPHARMA filings →

🔥 Also filed on 5 November 2025

VEDL Vedanta Limited Financial Results DELHIVERY Delhivery Limited Financial Results DELHIVERY Delhivery Limited Financial Results DELHIVERY Delhivery Limited Announcement DELHIVERY Delhivery Limited Announcement DELHIVERY Delhivery Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUNPHARMA files new disclosures

Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.